Comparison of different insulin regimens in elderly patients with NIDDM

Diabetes Care

Volumn 19, Issue 12, 1996, Pages 1326-1332

  Wolffenbuttel, Bruce H R ^a   Sels, Jean Pierre J E ^a   Rondas Colbers, Gabriëlle J W M ^a   Menheere, Paul P C A ^a   Nieuwenhuijzen Kruseman, Arie C ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; ISOPHANE INSULIN;

AGED; AGING; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0029856213     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.19.12.1326     Document Type: Article

References (29)

1. Skyler JS: Non-insulin-dependent diabetes mellitus: a clinical strategy Diabetes Care 7 (Suppl. 1):118-129, 1984
2. Gerich JE: Drug therapy: oral hypoglycemic agents. N Engl J Med 321:1231-1245, 1989
3. Tattersall RB, Scott AR: When to use insulin in the maturity onset diabetic. Postgrad Med J 63:859-864, 1987
4. Genuth S: Management of the adult onset diabetic with sulfonylurea drug failure. In Endocrinology and Metabolism Clinics of North America. Diabetes Mellitus - Perspectives on Therapy. Vol. 21. Karam JH, Ed. Philadelphia, Saunders, 1992, p. 351-370
5. Wolffenbutlel BHR, Weber RFA, Van Koetsveld PM, Weeks L, Verschoor L: A randomized crossover study of sulfonylurea and insulin treatment in patients with type 2 diabetes poorly controlled on dietary therapy. Diabetic Med 6:520-525, 1989
6. Lindstrom T, Arnqvist HJ, Olsson AG: Effect of different insulin regimens on plasma lipoprotein and apolipoprotein concentrations in patients with noninsulin-dependent diabetes mellitus. Atherosclerosis 81:137-144, 1990
7. Bagdade JD, Buchanan WE, Kuusi T, Taskinen M-R: Persistent abnormalities in lipoprotein composition in noninsulin-dependent diabetes alter intensive insulin therapy. Arteriosclerosis 10:232-239, 1990
8. Montgomery BJ: High plasma insulin level a prime risk factor for heart disease. JAMA 241:1665, 1979
9. Stout RW: The role of insulin in atherosclerosis in diabetics and nondiabetics. Diabetes 30 (Suppl. 2):54-57, 1981
10. Nilsson A, Tideholm B, Kalen J, Katzman P: Incidence of severe hypoglycemia and its causes in insulin-treated diabetics. Acta Med Scand 224:257-262, 1988
11. Wolffenbuttel BHR: Combined use of insulin and oral hypoglycaemic agents in the treatment of patients with diabetes mellitus. Eur J Int Med 1:89-95, 1989
12. Riddle MC, Hart JS, Bouma DJ, Phillipson BE, Youker G: Efficacy of bedtime NPH insulin with daytime sulfonylurea for subpopulation of type II diabetic subjects. Diabetes Care 12:623-629, 1989
13. Riddle MC: Evening insulin strategy. Diabetes Care 13:676-686, 1990
14. Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rajala S, Ryysy L, Salo S, Seppala P: Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 327:1426-1433, 1992
15. Stenman S, Groop PH, Saloranta C, Totterman KJ, Fyhrqvist F, Groop L: Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents. Diabetologia 31:206-213, 1988
16. World Health Organization: WHO Expert Committee on Diabetes Mellitus. Second Report. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DE, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419. 1985
18. Thoelke H, Ratzmann KP: Häufigkeit des Sekundärversagens einer Sulfonylharnstofftherapie-Epidemiologische Untersuchung. Dtsch Med Wschr 114:580-583, 1989
19. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D: Secondary failure to treatment with oral antidiabetic agents in non-insulm-dependent diabetes. Diabetes Care 9:129-133, 1986
20. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
21. Lazarus SS, Volk BB: Physiological basis of the effectiveness of combined insulin-tolbutamide therapy in stabile diabetes. Ann N Y Acad Sci 82:590-602, 1959
22. Feinstein AR: The persistent clinical failures and fallacies of the UGDP study. Clin Pharmacol Therap 19:78-93, 1976
23. Hamelbeck H, Klein W, Zoltobrocki M, Schooling K: Glibenclamide-insulin combination in the management of secondary failure of sulfonylurea medication. Dtsch Med Wschr 107:1581-1583, 1982
24. Osei K, O'Dorisio TM, Falko JM: Concomitant insulin and sulfonylurea therapy in patients with type II diabetes: effects on glucoregulation and lipid metabolism. Am J Med 77:1002-1009, 1984
25. Groop L, Hamo K, Nikkila EA, Pelkonen R, Tolppanen EM: Transient effect of the combination of insulin and sulfonylurea (glibenclamide) on glycemic control in non-insulin-dependent diabetics poorly controlled with insulin alone. Acta Med Scand 217:33-39, 1985
26. Taskinen MR, Sane T, Helve E, Karonen SL, Nikkila EA, Yki-Jarvinen H: Bedtime insulin for suppression of overnight free-fatty acid, blood glucose, and glucose production in NIDDM. Diabetes 38:580-588, 1989
27. Wolffenbuttel BHR, Leurs PB, Sels JPJE, Rondas-Colbers GJWM, Menheere PPCA, Nieuwenhuijzen Kruseman AC: Improved blood glucose control by insulin therapy in type 2 diabetic patients has no effect on lipoprotem(a) levels. Diabetic Med 10:427-430, 1993
28. Wolffenbuttel BHR, Weber RFA, Van Koetsveld PM, Weeks L, Verschoor L: A randomized crossover study of sulfonylurea and insulin treatment in patients with type 2 diabetes poorly controlled on dietary therapy. Diabetic Med 6:520-525, 1989
29. Castillo M, Scheen AJ, Paolisso G, Lefebvre PJ: The addition of glipizide to insulin therapy in type II diabetic patients with secondary failure to sulfonylureas is useful only in the presence of a significant residual insulin secretion. Acta Endocrinol 116:364-372, 1987